Interpretation and Management of EF 42%, FS 21%, Mild MR, Mild TR
You have heart failure with mildly reduced ejection fraction (HFmrEF) that requires initiation of guideline-directed medical therapy with SGLT2 inhibitors as first-line treatment, along with close monitoring for progression of your valve disease.
Interpretation of Findings
Your echocardiogram shows:
- EF 42% = HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): This falls in the 41-49% range, indicating your heart's pumping function is moderately impaired 1, 2
- FS 21% = Reduced fractional shortening: Confirms reduced systolic function (normal is typically >25%)
- Mild MR + Mild TR together: This combination is clinically significant and associated with worse survival compared to patients without valve abnormalities, even with your EF level 3
Critical Context
The combination of mild secondary mitral and tricuspid regurgitation in the setting of HFmrEF is not benign. Research demonstrates that patients with both mild MR and mild TR have a 21% increased hazard of death compared to those without valve abnormalities (HR 1.21,95% CI 1.12-1.31), and this holds true even with preserved EF 3. Your functional valve regurgitation likely represents ventricular functional mitral regurgitation (VFMR) given your reduced EF, as VFMR predominates in 87.8% of HFmrEF patients 4.
Management Strategy
1. Immediate Pharmacotherapy Initiation
The 2025 Canadian guidelines now unify HFmrEF and HFpEF under "HFnrEF" (nonreduced EF, LVEF >40%) because patients across this spectrum respond consistently to key therapies 2. You should receive:
First-Line Therapy:
- SGLT2 inhibitors (dapagliflozin or empagliflozin) - Strongest recommendation for reducing HF hospitalization and improving quality of life 2
Additional Foundational Therapies to Consider:
- Mineralocorticoid receptor antagonists (MRAs) - spironolactone or eplerenone 2
- ARNIs (sacubitril/valsartan) if symptomatic 2
- GLP-1 receptor agonists if you have obesity or diabetes 2
2. Aggressive GDMT Optimization
Contemporary evidence shows that 75% of patients with ≥moderate MR/TR achieve regression to mild or less with optimal GDMT 5. The key is achieving maximal tolerated doses of multiple GDMT medications - patients who received fewer GDMT medications had less valve regression and more progression 5.
3. Close Monitoring Protocol
Serial echocardiography every 6-12 months is essential because:
- MR progression independently predicts cardiovascular events in HFmrEF (HR 3.014) 4
- 35.9% of HFmrEF patients with moderate-to-severe FMR experience progression 4
- Early detection of progression allows timely intervention before irreversible RV dysfunction develops
Monitor specifically for:
- Worsening MR/TR severity
- RV function deterioration (TAPSE, RVFAC, RV strain)
- Symptoms (NYHA class, exercise tolerance)
- Natriuretic peptides (NT-proBNP)
4. Intervention Thresholds
Consider transcatheter intervention if:
- MR/TR progresses to moderate-severe despite optimal GDMT
- Symptoms worsen (NYHA III-IV) despite medical therapy
- RV function deteriorates
- Recurrent HF hospitalizations occur
The threshold for intervention has shifted toward earlier treatment, particularly with expanding transcatheter options 6.
Common Pitfalls to Avoid
Don't dismiss "mild" valve disease as benign - the combination of mild MR + mild TR carries significant mortality risk 3
Don't undertitrate GDMT - patients with mildly reduced EF often receive less aggressive therapy than those with more severely reduced EF, but they benefit equally 5
Don't delay SGLT2 inhibitor initiation - this is now first-line therapy regardless of diabetes status 2
Don't ignore RV function - TR and RV dysfunction are major determinants of outcomes and must be serially assessed 7, 8
Don't wait for severe valve disease - intervene when progression occurs despite optimal medical therapy, not just when reaching "severe" thresholds 6